The phase III GEMSTONE-301 study demonstrated the efficacy and safety of the anti-PD-L1 antibody sugemalimab as consolidation therapy in patients with locally advanced/unresectable stage 3 non-small cell lung cancer without disease progression after concurrent or sequential chemoradiotherapy.
To access this subscriber-only content please log in or renew your subscription.
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe